<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7577480</article-id><article-id pub-id-type="pmc">2033922</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kerr</surname><given-names>D. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rustin</surname><given-names>G. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaye</surname><given-names>S. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Selby</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bleehen</surname><given-names>N. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harper</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brampton</surname><given-names>M. H.</given-names></name></contrib></contrib-group><aff>University of Birmingham CRC Institute for Cancer Studies, Queen Elizabeth Hospital, UK.</aff><pub-date pub-type="ppub"><month>11</month><year>1995</year></pub-date><volume>72</volume><issue>5</issue><fpage>1267</fpage><lpage>1269</lpage><abstract><p>Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00045-0207.tif" xlink:title="scanned-page" xlink:role="1267" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00045-0208.tif" xlink:title="scanned-page" xlink:role="1268" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00045-0209.tif" xlink:title="scanned-page" xlink:role="1269" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

